Technologies rarely advance at a steady and predictable pace, but new platforms and newer ideas are already shaping the future of clinical lab testing. This article from the April 2014 issue highlights a handful of companies that are working to bring new diagnostic technologies to market and improve patient care.
For every test that has been accepted for use in clinical laboratories, scores of others have been dropped.
Exclusive partnership between Beckman Coulter Diagnostics and hc1.com will bring innovative healthcare cloud technology to clinical laboratories.
Since last November, when FDA cleared Illumina’s MiSeqDx high-throughput sequencer for diagnostic applications, the potential of next-generation sequencing has captured the imagination of many scientists and laboratorians—and with it their engagement in developing clinical tests based on Illumina’s platforms.
Founded in 2012 in La Jolla, Calif, Electrozyme is endeavoring to become the world leader in the development of printed electrochemical biosensors. The company offers a portfolio of printed biosensors that facilitate high-fidelity amperometric, voltammetric, and potentiometric electrochemical analyses of numerous compounds relevant to the healthcare, environmental sensing, and security monitoring domains.
Researchers at the University of Washington are working to develop a handheld, paper-based device that could detect infectious diseases using samples collected and tested at the point of care. The technology could hold promise for pathogen identification in remote areas, as well as densely populated areas such as hospitals, prisons, and military bases.
Since the Bruker MALDI Biotyper first came on the market in 2007, more than 1,000 microbiology labs worldwide have acquired the system. This robust MS instrument and procedure offers the benefits of results in less than five minutes, throughput of approximately 200 samples per hour, and low cost per test.
Thermo Fisher Scientific and researchers at Harvard Medical School have teamed up to develop promising new ways to perform protein quantitation on a much larger scale than currently possible, with the goal of accelerating the discovery of effective therapies.
Menssana Research laboratories have established a new role for breath testing in the early detection of disease. Scientists there have developed a portable breath collection apparatus that can collect breath samples for highly sensitive laboratory analysis virtually anywhere.
Headquartered in Halifax, Nova Scotia, Canada, MedMira is developing a robust pipeline of tests based on its patented Rapid Vertical Flow technology. The technology facilitates the formation of highly specific antigen-antibody reactions, allowing specific biomarkers in many sample types—including human whole blood, serum, or plasma—to be captured and visualized on a unique membrane.
Diagnostics giant bioMérieux had more than one reason to celebrate last year. Not only did the company mark its 50th anniversary, it also gained first-to-clinical-market advantage with the launch of its new diagnostic platform, dubbed Vitek MS.